*Update*: ASCO 2025 puts Daraxonrasib at the centre of pancreatic cancer debate

At the ASCO Congress 2025, two topics dominate discussions around pancreatic cancer: the scientific progress promised by active ingredients like Daraxonrasib, and the structural barriers that make this progress unreachable for many affected individuals. STAT News summarises that the congress has sparked not only new treatment data but also broad debates about access inequalities in cancer care – a tension that characterises the entire conference.

Researcher Vilma Pacheco Barcia is among the voices at ASCO who describe international collaboration as key to faster progress in pancreatic cancer. Oncodaily reports that Pacheco Barcia emphasises the importance of cross-border study designs – especially because the disease, with its poor prognosis, requires rapid, coordinated responses.

In parallel, a doctoral student from Wayne State University presented his research on pancreatic cancer on a national stage. Today@Wayne reports that the cancer biology doctoral student examined molecular mechanisms that could provide new therapeutic targets in the long term – an indication of how broadly basic research is positioned in this field.

Hope and care reality

The broader context in which Daraxonrasib is discussed becomes clearly apparent at ASCO: while individual active ingredients inspire hope, the reality of care remains complex. STAT News notes that access barriers – from costs to geographical availability of clinical trials – remain central topics at the congress. For patients with metastatic pancreatic cancer, this means: even if a drug like Daraxonrasib doubles survival time, it is often the health system that determines who benefits from it.

The mood at the congress is described by epidemiologist Devi Sridhar in the Guardian as a coexistence of genuine progress and persistent inequalities – hope and disillusionment at once. This image precisely reflects the current debate around Daraxonrasib: a scientific breakthrough whose social realisation is still pending.